WHO WE SERVE

Six teams. One throughline: evidence.

We partner with healthcare organizations at the moments that decide whether an innovation reaches the market — from a founder’s first U.S. step to an enterprise portfolio to a public-health campaign. Different stage, different stakes, same discipline: build the evidence, then make it work for both authorization and adoption.

PARTNER ONE

Close-up image of a crib with a red blanket or cover at the head of the crib.

Non-US early-stage device founders

The Challenge:

You’ve got a validated product and a plan to enter the world’s largest healthcare market — but the U.S. runs on rules you didn’t write: FDA pathways, payer dynamics, coding, coverage. The costliest mistakes happen early, when you’re generating evidence for the wrong audience.

How We Help:

We tell you what evidence the U.S. market will demand before you spend to generate it — then help you build the market case around it. You enter with a roadmap, not a guess.

What It Looks Like:

03.

Evidence Strategy
Review

04.

Business
Plan

02.

Market
Landscape

01.

Founder’s
Workshop

PARTNER TWO

Progress bar with a light blue section, a red section, and three large red dots on the right.

Healthcare & device VCs

The Challenge:

Every deal looks promising in the pitch. The question is whether it’s clinically feasible, regulable, and reimbursable — before you commit.

How We Help:

We pressure-test the evidence and the regulatory logic behind a venture, so your diligence rests on what the FDA, CMS, and payers will actually require — not on the founder’s optimism.

What It Looks Like:

03.

Evidence & Regulatory Assessment

04.

Industry Analysis

02.

Pitch & Diligence Review

01.

VC
Advisory

PARTNER THREE

Close-up of a red ink stamp on a white paper document with printed text.

Non-US & US device scale-ups

The Challenge:

You’ve got early traction. Now you need durable U.S. growth — coverage locked, positioning sharp, go-to-market real.

How We Help:

We connect the dots between evidence, coverage, and commercial story so your growth compounds instead of stalling at the next payer or the next market.

What It Looks Like:

02.

Regulatory & Reimbursement Review

04.

Industry Analysis

03.

Evidence & Regulatory Assessment

01.

Market Landscape

PARTNER FOUR

A thermometer showing a high temperature, with the red indicator close to the maximum.

Large device manufacturers

The Challenge:

Across a complex portfolio, evidence and coverage strategy drift out of sync, and even strong clinical data underperforms as a market narrative.

How We Help:

We align evidence and coverage strategy across products and sharpen the clinical story so it persuades as well as it complies — one evidence base, working everywhere.

What It Looks Like:

02.

Regulatory & Reimbursement Review

01.

Evidence Strategy Review

04.

Custom Consulting

03.

KOL
Visibility

PARTNER FIVE

Close-up of a red video game controller.

U.S. healthcare services companies

The Challenge:

You’ve got proven traction. What’s holding you back is positioning, messaging, and a go-to-market motion built to scale.

How We Help:

We ground your positioning in evidence and outcomes — not slogans — so growth-stage messaging earns trust with the clinical and enterprise buyers who matter.

What It Looks Like:

01.

GTM For Healthcare Companies

03.

Marketing
Strategy

02.

Positioning & Messaging

PARTNER SIX

Progress bar with a light blue section and a red section, ending with four red circles.

Advertisers & communications firms serving public health

The Challenge:

You’re accountable for public-health campaigns that have to change real behavior — and stand up to clinical and community scrutiny.

How We Help:

We supply the evidence base and clinical validation your creative is built on, so campaigns are accurate, persuasive, and measurable against health outcomes. You bring the reach; we make sure it’s grounded.

What It Looks Like:

01.

Public Health Campaign Strategy

03.

KPI-To-Outcome Design

02.

Clinical
Validation

Don’t see your exact situation?

If it involves getting a health innovation authorized, adopted, or both, evidence is still the answer — and it’s still what we do.